Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended		0 Months Ended	12 Months Ended	1 Months Ended		12 Months Ended	0 Months Ended	1 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Feb. 27, 2014	Dec. 31, 2014	Mar. 31, 2015	Dec. 31, 2007	Dec. 31, 2012	Jun. 15, 2012 patients	Aug. 28, 2012 patients	Jun. 20, 2014	Sep. 30, 2014	Jul. 31, 2013
Commitments and Contingencies (Textual)
Research recorded fees	$ 4,048,714us-gaap_ResearchAndDevelopmentExpense	$ 1,589,776us-gaap_ResearchAndDevelopmentExpense
Total project estimated to cost										800,000us-gaap_DevelopmentInProcess
Letter of credit	34,733us-gaap_LineOfCredit				34,733us-gaap_LineOfCredit
Amount paid to goodwin	1,849,000atnm_AmountPaidToGoodwin	522,000atnm_AmountPaidToGoodwin
Manufacturing Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost for clinical trials of drug Ac-225-HuM195			2,100,000
Non - refundable institutional fee			562,790
Total project estimated to cost			3,300,000
Research and development costs	200,000			100,000
Einstein [Member]
Commitments and Contingencies (Textual)
Research recorded fees	55,000	0			146,713
Total project estimated to cost											183,391
Abbview Biotherapeutics Corp [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
License fee payment	3,000,000
Milestones payments	7,750,000
Description of royalty payment	The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.
Royalty of net sales percentage	12.00%
Abbview Biotherapeutics Corp [Member] \| After First Net Sales [Member]
Commitments and Contingencies (Textual)
Milestones payments	1,500,000
Abbview Biotherapeutics Corp [Member] \| Phase I Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones payments	750,000
Abbott Biotherapeutics Corp [Member] \| After First Net Sales [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
Net sales in milestones payment	10,000,000
Abbott Biotherapeutics Corp [Member] \| Phase I Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
First commercial sale period	750,000
Aptiv Solutions [Member]
Commitments and Contingencies (Textual)
Down payment of project estimated cost percentage	12.50%
Down payment for project						239,000	239,000
Accrued expenses	0	100,000			0
Total project estimated to cost	1,900,000				1,900,000
Fred Hutchinson Cancer Research Center [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Milestones payments								1,000,000
Description of royalty payment								Royalty payments of 2% of net sales will be due to FHCRC.
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )								150,000
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )								250,000
Number of Patients								2
Accrued expenses	46,000	37,500			46,000
Fred Hutchinson Cancer Research Center [Member] \| Maximum [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration								23,500,000
Fred Hutchinson Cancer Research Center [Member] \| Minimum [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration								13,200,000
University of Texas M.D. Anderson Cancer Center [Member] \| Clinical Trial Agreement [Member]
Commitments and Contingencies (Textual)
Number of Patients									24
Amount paid to each patient after Completing clinical trial												34,383
Start-up fee for clinical trial									33,946
Non - refundable institutional fee									14,500
Total project estimated to cost									$ 500,000